Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

CUB Erasme Hospital, Brussels

Cliniques Universitaires Saint-Luc, Brussels

Universitair Ziekenhuis Antwerpen, Edegem

AZ Maria Middelares, Ghent

UZ GENT, Ghent

University of Virginia, Charlottesville

Central Virginia VA Healthcare System, Richmond

Chu Rangueil, Toulouse

Prolive Medical Research, Miami

CHU Bordeaux, Pessac

Galenus Group, Lehigh Acres

Florida Research Institute, Lakewood Rch

Birmingham Digestive Health Research, Homewood

Digestive Health Research, Hermitage

Indiana University School of Medicine, Indianapolis

Digestive Health Research of Southern California, South Bend

CHU Angers_Service d'hepatogastro-enterologie, Angers

HGE CHRU Nancy, Vandœuvre-lès-Nancy

Mayo Clinic, Rochester

Tandem Clinical Research - New Orleans Area Site, Marrero

ARcare Center for Clinical Research, Conway

ARcare Center for Clinical Research, Little Rock

Hopital Saint Antoine, Paris

Dallas Diabetes Research Center, Dallas

Digestive Health Research of North Texas, Wichita Falls

Impact Research Institute, Waco

American Research Corporation, San Antonio

Diabetes & Glandular Disease Clinic, P.A., San Antonio

Accelemed Research Institute, Austin

Institute for Liver Health dba Arizona Liver Health, Chandler

CHU Limoges, Limoges

Velocity Clinical Research, Gardena

National Research Institute, Huntington Park

Cadena Care Institute, LLC, Poway

Cure Clinical Research, LLC, Fountain Valley

Harvard Medical School, Boston

AIG Digestive Disease Research, Florham Park

Amsterdam UMC, Amsterdam

Hull University Teaching Hospital, Hull

King's College Hospital, London

St Georges Hospital, London

Royal Victoria Infirmary, Newcastle upon Tyne